1. World Health Organization. Cardiovascular diseases
(CVDs) [ online ]. Available from URL: http://
www.who.int/mediacentre/ factsheets/fs317/en/inex.html
2. Murray CJL, Lopez AD Alternative projections of mortality
and disability by cause 1990-2020: Global burden of disease
study Lancet 1997; 349: 1498-1504.
3. Emberson JR, Whincup PH, Morris RW Walker M. Reassessing
the contribution of serum total cholesterol, blood
pressure and cigarette smoking to the aetiology of coronary
heart disease: impact of regression dilution bias. European
Heart Journal 2003; 24: 1719–26.
4. World Health Organization. Reducing risks, promoting
healthy life. The world health report 2002.
5. World Health Organization: Gaining Health: The European
Strategy for the Prevention and Control of noncommunicable
diseases. WHO Regional Committee for
Europe www.euro.whu.int/Document/RC56/edoc08.
6. De Backer G; EUROASPIRE II Study Group. Evidence-based
goals versus achievement in clinical practice in secondary
prevention of coronary heart disease: findings in EUROASPIRE
II. Atheroscler Suppl. 2002; 13-6;16-7.
7. De Sutter J, De Bacquer D, Kotseva K, Sans S, Pyorala K,
Wood D, De Backer G; EUROASPIRE II Study Group. Screening
of family members of patients with premature coronary
heart disease; results from the EUROASPIRE II family
survey. Eur Heart J. 2003; 24: 249-57.
8. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C,
Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham
I, Mancia G, Cats VM, Orth-Gomér K, Perk J, Pyörälä K,
Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen
T, Wood D; European Society of Cardiology Committee for
Practice Guidelines. European guidelines on cardiovascular
disease prevention in clinical practice: third joint task force
of European and other societies on cardiovascular disease
prevention in clinical practice (constituted by representatives
of eight societies and by invited experts). Eur J Cardiovasc
Prev Rehabil. 2003; 10(4):S1-S10.
9. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau
JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin
or Atorvastatin Evaluation and Infection Therapy-
Thrombolysis in Myocardial Infarction 22 Investigators.
Intensive versus moderate lipid lowering with statins after
acute coronary syndromes. N Engl J Med. 2004 Apr
8;350(15):1495-504.
10. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S,
Yin D. Lipid-modifying therapy and attainment of cholesterol
goals in Europe: the Return on Expenditure Achieved for
Lipid Therapy (REALITY) study. Curr Med Res Opin. 2005; 21:
1389-99.
11. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT,
Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National
Heart, Lung, and Blood Institute;American College of
Abant Med J 2012;1(2):89-93 93
Cardiology Foundation; American Heart Association.
Implications of recent clinical trials for the National
Cholesterol Education Program Adult Treatment Panel III
guidelines. Circulation. 2004; 110: 227-39.
12. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C,
Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham
I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyörälä
K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen
T, Wood D; Third Joint Task Force of European and
Other Societies on Cardiovascular Disease Prevention in
Clinical Practice. European guidelines on cardiovascular
disease prevention in clinical practice. Third Joint Task Force
of European and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice. Eur Heart J. 2003; 24 :1601-
10.
13. Pineda J, Marín F, Marco P, Roldán V, Valencia J, Ruiz-
Nodar JM, Romero DH, Sogorb F, Lip GY. The prognostic
value of biomarkers after a premature myocardial infarction.
Int J Cardiol. 2010; 143: 249-54.
14. Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I; WOSCOPS
Group. Factors affecting low-density lipoprotein and
high-density lipoprotein cholesterol response to pravastatin
in the West Of Scotland Coronary Prevention Study (WOSCOPS).
Am J Cardiol. 2002; 90: 731-6.
15. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart
JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters
D.Effect of lowering LDL cholesterol substanitially below
currently recommended levels in patients with coronary
heart disease and diabetes: The Treating to New Targets
(TNT) Study. Diabetes Care. 2006; 29: 1220-1226.
16. Ford I, Blauw GJ, Murphy MB, Shepherd J, Cobbe SM,
Bollen EL, Buckley BM, Jukema JW, Hyland M, Gaw A, Lagaay
AM, Perry IJ, Macfarlane P, Norrie J, Meinders AE,
Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott
DJ; The PROSPER Study Group. A Prospective Study of Pravastatin
in the Elderly at Risk (PROSPER): Screening Experience
and Baseline Characteristics. Curr Control Trials
Cardiovasc Med. 2002: 20; 8.
17. Williams B, Lacy PS, Cruickshank JK, Collier D, Hughes
AD, Stanton A, Thom S, Thurston H; CAFE and ASCOT Investigators.
Impact of statin therapy on central aortic pressures
and hemodynamics: principal results of the Conduit Artery
Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
Circulation. 2009; 119:53-61.
18. Spaulding C, Weber S. Scandinavian simvastatin study
(4S). Lancet. 1994; 344:8939-8940.
19. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA,
Bernstein V, Cuddy TE, Moyé LA, Piller LB, Rutherford J,
Simpson LM, Braunwald E. Reduction of stroke incidence
after myocardial infarction with pravastatin: the Cholesterol
and Recurrent Events (CARE) study. The Care Investigators.
Circulation. 1999; 19: 216-23.
20. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J,
Simes J, White H. Effects of lowering average of belowaverage
cholesterol levels on the progression of carotid
atherosclerosis: results of the LIPID Atherosclerosis
Substudy. LIPID Trial Research Group. Circulation. 1998; 97:
1784-90.
21. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine
MS, Jarolim P, Shui A,
McCabe CH, Braunwald E; PROVE IT-TIMI 22 Investigators.
Intensive statin therapy and the risk of hospitalization for
heart failure after an acute coronary syndrome in the PROVE
IT-TIMI 22 study. J Am Coll Cardiol. 2006; 47: 2326-31.
22. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G,
Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R;
Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy
and safety of cholesterol-lowering treatment: prospective
meta-analysis of data from 90,056 participants in 14 randomised
trials of statins. Lancet. 2005; 8: 366(9493):1267-
78.
23. Hockley T, Pollard S, Smedley M. Lifestyle and risk factor
management and the use of drug therapies in coronary
patients from 15 countries. Principal results from EUROASPIRE
II. European Heart Journal 2001; 22: 554-572.
Thank you for copying data from http://www.arastirmax.com
